Progyny, Inc. (PGNY) Hit a 52 Week High, Can the Run Continue?
Progyny (PGNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Why Progyny (PGNY) Might be Well Poised for a Surge
Progyny (PGNY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Are You Looking for a Top Momentum Pick? Why Progyny (PGNY) is a Great Choice
Does Progyny (PGNY) have what it takes to be a top stock pick for momentum investors? Let's find out.
What Makes Progyny (PGNY) a New Strong Buy Stock
Progyny (PGNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Progyny, Inc. (PGNY) Shareholder/Analyst Call Transcript
Progyny, Inc. (PGNY) Shareholder/Analyst Call Transcript
Bull of the Day: Progyny (PGNY)
For growth investors seeking exposure to a differentiated healthcare disruptor with strong secular tailwinds, Progyny (PGNY) stock deserves a close look.
Progyny, Inc. (PGNY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Progyny, Inc. (PGNY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Progyny Q1 Earnings Call Highlights
Progyny NASDAQ: PGNY reported what management called a strong start to 2026, with first-quarter revenue reaching a record level and profitability exceeding expectations amid continued investments in its platform and member experience.
Progyny, Inc. (PGNY) Q1 2026 Earnings Call Transcript
Progyny, Inc. (PGNY) Q1 2026 Earnings Call Transcript
Progyny (PGNY) Q1 Earnings and Revenues Beat Estimates
Progyny (PGNY) came out with quarterly earnings of $0.5 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.48 per share a year ago.
Should Value Investors Buy Progyny (PGNY) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Progyny (PGNY) Upgraded to Buy: Here's Why
Progyny (PGNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
